Type i (insulin-dependent) diabetes mellitus has been proposed since Epstein-Barr virus BOLF1(497-513) AVTPL RIFIVPPAAEY has an 11 amino acid identity with HLA-DQw8/3 (49-60) AVTPL GPPAAEY. Rabbit antisera to the B OLF1(496-515) peptide crossreacted with the homologous DQw8fl (44-63) peptide but not with the related DQw7fl (44-63) peptide, which differed from the DQw8 peptide only in an ALA to ASP substitution in position 57. Antisera to DQw8/3 (49-60) reacted with the DQw8fl(44-63) peptide and BOLF1 (496-515), but not with D Qw7/3 (44-63). The antiserum to the BOLF1 peptide bound to denatured class II major histocompatibility complex/3 chains from Epstein-Barr virus-transformed DQw8-positive lymphocytes in an immunoblotting analysis. Epstein-Barr virus antibodies were detected at equal frequencies and similar titres in sera of 30 patients with Type 1 diabetes (16 of 30; 63% ) and in sera of 20 non-diabetic control subjects (13 of 20; 65%). Sera from diabetic patients did not bind to peptides. From these data we conclude that there is no simple relationship between serological evidence of Epstein-Barr virus infection and crossreactions between homologous Epstein-Barr virus and class II major histocompatibility complex peptides.
The molecular mimicry hypothesis for the origin of autoimmune disease proposes that sequence homology between a protein of a pathogen and an organ-specific, self protein can trigger an autoimmune response [1] . Evidence for this hypothesis is found in peptide homologies between Klebsiella pneumoniae nitrogenase and HLA-B27 in the case of ankylosing spondylitis [2] , and between adenovirus E1B protein and a-gliadin in coeliac disease [3] . For Type 1 (insulin-dependent) diabetes mellitus, acute coxsackie virus B4, persistent cytomegalovirus, and rubella virus infections may precede the clinical onset [4] [5] [6] [7] , but diabetes-eliciting sequences of these viruses have not been proposed. Environmental factors must contribute to the pathogenesis of Type 1 diabetes, since the concordance rate for the disease in monozygotic twins is about 35% [8] . Genetics also influence the incidence of the disease, since certain class II major histocompatibility complex (MHC) alleles are closely linked to disease susceptibility [9] . The role of those alleles of class II MHC antigens, especially of HLA-DQ, in the pathogenesis of Type i diabetes remains obscure. HLA-DR4 is in linkage disequilibrium with two different alleles of HLA-DQ, -DQw7, and -DQw8, of which the DQw8 allele is increased among Type I diabetic patients [10] . Within the first domain, these two fl-chain alleles differ only by 4 amino acids at positions 13, 26, 45, and 57 and it has been suggested that the residue in position 57 may be particularly important [10, 11] .
Linkages between MHC alleles and diabetes could reflect either MHC restriction of presentation of foreign antigens, and homologous autoantigens, or presentation of a segment of the MHC molecule itself. Homologies between antigens and peptides forming the antigen-binding site (desetope) of class II MHC molecules have been suggested as leading to tolerance [12] . Highly conserved, basic dipeptide sites about the class II MHC desetopes could lead to excision of such segments of those molecules and presentation to the immune system (L.J. Thomas (Table 1) . BOLF1 is a gene for a hypothesized product of unknown function from BamHI restriction endonuclease fragment O, leftward open reading frame in the B95-8 EBV genome [14] . Furthermore, HLA-DQw8fl (53-60) brackets the 57th residue which is strongly linked to diabetes susceptibility (VAL 57, SEN 57, ALA 57) or resistance (ASP 57) [10, 11] . That DQfl-chain sequence, including the diabetes-resistance-correlated ASP s7, is at the end of a helix forming one wall of the antigen-binding site (desetope) [15] . We tested whether serological crossreaction occurred between the homologous sequences of DQw8fl and BOLF1, and we analysed sera of recent onset, Type 1 diabetic patients for the presence of EBV antibodies.
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Materials and methods
Peptide syntheses and immunizations
Peptides were synthesized by a solid-phase method [16] and purified by step gradient elution from a reverse-phase column in 2% acetic acid with increasing concentrations of acetonitrile. The identity of each peptide was confirmed by analyses of amino acid composition and sequence. Antisera to DQw7fl (4%60), DQwSfl(4%60) [17] and BOLF1(496-515) were obtained after immunization of rabbits with keyhole limpet haemocyanin-coupled peptides. Peptide-specific antibodies to BOLF1(496-515) were purified by affinity chromatography on peptide-coupled Affi-Gel 10 (BioRad, Richmond, Calif., USA) [18] . The peptide-bound gel was incubated with antiserum, washed with 50 mmol/1Hepes buffer, 1 mmol/1 CHAPS, pH 7.5, and the specific antibodies were eluted in i mol/1 acetic acid and neutralized.
ELISA
Microtitre plates were incubated with 5 gg/ml peptide in 50 retool/1 NazCOJNaHCO3 buffer, pH 9.6, overnight at room temperature and were washed three times in phosphate-buffered saline solution (PBS) with 0.1% Tween 20 [19] . The plates were incubated with antisera or sera diluted in PBS containing 1% BSA and 0.1% Tween 20, at room temperature for 1.5 h, washed and incubated with peroxidase-conjugated F(ab')z goat-anti-rabbit IgG or goat-antihuman IgG (Zymed, South San Francisco, Calif., USA) for 1.5 h at room temperature. After washing, substrate (0.4 mg/ml 0-phenyldiamine and 0.03% hydrogen peroxide) was added. The reaction was stopped after 30 min with 2 mol/1 H2SO4 and the absorbance was measured at 490 nm. For competitive ELISA experiments, peptides were added to antisera prior to addition of those mixtures to peptide-coated, microtitre plates [19] .
Immunoblotting assays
EBV-transformed lymphoblasts (107 cells) were homogenized in 10 mmol/1 Hepes buffer, pH 7.4, containing 0.25 tool/1 sucrose, 10 mmol/1 benzamidine, 0.1 mmol/l p-chloromercuriphenyl sulfonic acid and 0.5% (weight/volume) aprotinin, and were centrifuged at 4~ for 30 min at 35000 x g [17] . The particulate fraction was solubilized for 2 h at 4 ~ in 10 mmol/1 Hepes, pH 7.4, with 150 mmol/1 NaC1, 10 retool/1 benzamidine, 0.63% (weight/voinme) aprotinin and 2% Triton X-114. The lysate was centrifuged for 15 rain at 4~ at 10 000 x g to remove nuclei and insoluble particles, and the supernatant was layered on a Hepes buffer with 6% sucrose [20] . The gradient was incubated at 30 ~ for 5 min, and amphiphilic membrane proteins were obtained by centrifugation at 1 500 x g for 3 min [20], The detergent-phase proteins were denatured under reducing conditions, subjected to SDS 10% polyacrylamide gel electrophoresis and electroblotted onto nitrocellulose filters. For immunostalning, nitrocellulose strips were incubated with antisera, washed, incubated with F(ab')z goat-anti-rabbit IgG-alkaline-phosphatase (Zymed), washed, and incubated in substrate buffer (150 mmol/[ NaC1, 5mmol/1 MgClz, 0.33 mg/ml nitroblue tetrazolium and 0.17 mg/ml 5-bromo-4-chloro-3-indolyl phosphate) [17] .
Patients and control subjects
For the first study, sera were obtained from 10 Swedish children who were within ]0 days of the diagnosis of Type 1 diabetes and were therapeutically plasmapheresed. Age, sex, and DR histotype ar e reported in Table 2 for each patient. In the second study, sera were obtained from 20 recent-onset, diabetic Swedish children and from 
Assays of EB V antibodies
Assays for pancreatic islet cell antibodies (ICA) and insulin autoantibodies (IAA )
Beta cell-specific autoantibodies, ICA, were assayed by a two-colour immunofluorescence technique in which a patient's serum was incubated with slides of human pancreatic tissue in the presence of a monoclonal antibody to proinsulin. FITC-labelled, anti-human IgG and Texas red-labelled, anti-mouse IgG served as second antibodies. ICA titres from serial dilutions of the sera were converted to Juvenile Diabetes Foundation (JDF) units with a standard curve generated from the JDF International reference sera [26, 27] . IAA was determined in a radioligand binding assay [28] . The BOLF1 (496-515) peptide was z25I-labelled by the chloramine-T method [29] and separated from flee iodide by step gradient elution from a reverse phase column. Serum was incubated for 60 min at 4 ~ with 125I-BOLFl(496-515) at 250000 cpm/sample in a final volume of 150 gl. That mixture was incubated for 30 min 4~ with protein ASepharose, 5 mg/sample, and immune complexes were isolated by centrifugation, washed twice, and the precipitated radioactivity was counted.
Results
In a comparison of the sequence of H L A -D Q w 8 f l to proteins of the Protein Identification Resource [30] , a region was found with 11 of 17 residues shared with an E B V protein, BOLF1 [13] , (Table 1) . To determine whether these sequences crossreacted serologically, antisera to each peptide were tested by E L I S A methods. Anti-BOLF1 (496-515) bound to the BOLF1 and DQw8fl (44-63) peptides with a high titre, but to the DQw7fl (44-63) peptide with a much lower titer, and not at all to an irrelevant peptide, papilloma virus, E2 protein (76-84) (Fig. 1) . Antisera to DQw8fl (49-60) bound DQw7fl (44-63) (A), DQw8fl (44-63) (B), and BOLF1(496-515) (C) (Fig.2 ). In contrast, antisera to DQw7fl (49-60) bound the DQw7fl (44-63) and DQwSfl (44-63) peptides, but not the BOLF1 (496-515) peptide. The binding of the BOLF1 antisera to DQw8fl (44-63) was inhibited by DQwSfl (44-63) and by the BOLF1 peptide, but not by the DQw7fl or the irrelevant papilloma virus peptide (Fig. 3) . The binding of anti-BOLF1 serum to BOLF1(496-515) was inhibited by the BOLF1 peptide, only. Affinity-purified antibodies to BOLF1(496-515) showed the same binding characteristics as did the antiserum (data not shown). Antisera from three of the four rabbits immunized with the BOLF1 peptide immunoblotted to a 29 kilodalton (kd) protein, presumably the class II M H C [3 chain, from HLA-DQw8-positive, transformed lymphoblasts (Fig. 4) . The binding to the 29 kd protein, was inhibited by BOLF1(496-5t5) or DQwSfl (44-63) peptides, but only partly by DQw7fl (44-63) or the irrelevant papilloma virus peptide. Similarly, affinity-purified antibodies to the BOLF1 peptide showed specific binding to the 29 kd protein in immunoblotting analysis (data not shown).
In order to determine whether recently diagnosed Type i diabetic patients had been infected with EBV, we tested sera from 10 children treated with plasmapheresis Table 2 ) each contained EBV antibodies, as shown in IgG VCA titres ranging from 1 : 80 to 1 : 640. Since IgM anti-VCA antibodies, which are detected in acute stages of the infection, were not detected, the patients were considered to have past, but not acute or early convalescent phase infections as seen in the course of infectious mononucleosis [31] . An IgG anti-EA titre > 1 : 20 was detected in only sera of patients with acute or chronic EBV infection [31] . One serum (No. 8) had abnormally high titres to VCA and EA, indicating a late stage of acute infection or a chronic infection.
In light of the concordance between EBV infection and diabetic status in these 10 patients, additional sera from diabetic patients and control subjects were tested (Nos. 11-50 of Table 2 ). EBV antibodies to both VCA and EBNA were detected, respectively, in 9 of 20 and 12 of 20 sera of the patients and control subjects. Anti-EA antibodies ( > 1 : 20) were detected in 6 of 30 (20%) or 3 of 20 (15%) of the patients and control subjekts, respectively (Table 2 and Fig. 5 ). These anti-EA-positive individuals (No. 8, 15, 24, 27, 30, 34, 36, 38 , and 39) must have had acute or chronic EBV infections, but no IgM anti-VCA antibody was detected (Table 2 ). There was no correlation between diabetic status and infection with EBV (Fig.5) . Also, among diabetic patients with EBV antibodies, there was no correlation between ICA and EBV antibodies ( Table 2) .
The presence of anti-BOLFl(496-513) antibodies in sera of diabetic patients was tested for by an ELISA. The peptides (0.107 + 0.067 and 0.066 + 0.042, respectively) or to uncoated ELISA plates (0.091 + 0.056). The sera of 45 recent onset diabetic children were also tested for binding to ~25I-BOLFl(496-515) in a radioligand assay. At a final serum dilution of 1:25 the mean binding (275 + 22 cpm) was not different from the non-specific binding of the radiolabelled peptide to protein A-Sepharose (276 + 10 cpm). In contrast, rabbit antiserum to BOLFl(496-515) at a final dilution of 1 : 1000 bound the radiolabelled peptide (35,219 cpm). This binding was specific since incubation with an excess of unlabelled BOLFl(496-515) reduced to 195 cpm.
Discussion
Finding a homology between sequences in EBV BOLF1 and the HLA-DQw8fl-related diabetes-susceptible DQ allele, led us to test whether those sequences crossreacted serologically. In ELISA rabbit antisera to BOLFl(496-515) and to DQw8/3 (49-60) reacted with the immunizing peptide and with the homologous peptide, but not with the closely related HLA-DQw7fl sequence in which ASP is substituted for ALA 57. ASP 57 correlates with diabetes resistance, while ALA, SER, or VAL at that position relate to diabetes susceptibility [10, 11] . Rabbit anti-BOLF1 (496-515) or anti-DQw8/3 (49-60) immunoblotted to a denatured DQw8fl-positive, EBV-transformed, lymphoblast protein of the molecular weight (29 kD) of class II MHC/3 chain. There was no evidence for recognition of native class II MHC/3 chains by anti-BOLF1(496-515) in immunofluorescence or immunoprecipitation assays. Also, antibodies to DQw8fl (44-63) or BOLF1(496-515) peptides were not detected in sera of patients with acute onset or long-term Type i diabetes. These studies demonstrated clearly the potential for immunological recognition of sequence homology and discrimination of the ALA-->ASP substitution in position 57. Homologous sequences have been found in class II MHC/3 chains and some viruses which infect humans. The IE-2 region of cytomegalovirus shares a five amino acid segment with a conserved region of the first domain of HLA-DR/3-chain, showing immunological crossreactivity [32] . This homology might enhance graft rejection when cytomegalovirus infection follows organ transplantation. Other homologies between rubella virus [33] and EBV [34, 35] , and HLA-DR and -DQ/%chain sequences have been suggested to lead to Type I diabetes and rheumatoid arthritis, respectively. Human immunodeficiency virus (HIV) gp41 (838-844) shares 4 of 6 amino acids with HLA-DR(19-25) and HLA-DQ/3(19-25) [36] . Since antibodies from n.d. = not determined; VCA = viral capsid antigen; EBNA = nuclear antigen some patients with AIDS reacted with the class II MHC/3 peptide and intact class II MHC molecules, the reaction of anti-HIV antibodies with self class II MHC antigens was proposed to alter class II MHC-mediated immune responses, contributing to immunodeficiency [36, 37] . Proliferative responses of normal CD4 + T cells to tetanus toxoid and alloantigens were inhibited by antisera to class II MHC molecules [37] . In our study, diabetic patients did not demonstrate antibodies to the unfolded peptides or denatured, electrophoresed class II MHC/3 chain molecules. The lack of such serological recognition of denatured determinants did not exclude serological recognition of native determinants, or of excised fragments by T cells. If EBV were the principal, predisposing pathogen for Type 1 diabetes, as one might suppose from our serological study of the homologous epitopes in EBV BOLF1 and some class II MHC/3 chains, then one might expect increased titres of anti-EBV antibodies in the sera of patients with acute onset, Type 1 diabetes. We therefore as-sayed sera from 10 children with acute onset Type 1 diabetes at the onset of their disease. All of those patients had EBV antibodies. We extended this study to coded samples of 20 additional patients at the onset of diabetes and 20 age-and sex-matched children without diabetes. These latter 40 sera demonstrated no correlation between EBV infection and diabetes. The failure to relate serological evidence of EBV to Type i diabetes indicates that there is no simple relationship between EBV infections and the homologies and crossreactions which exist between some EBV proteins and class II MHC molecules. Further studies of concident cases and matched control subjects from one geographical area might be required to disprove, conclusively at an epidemiological level, the hypothesis that EBV infection is causally related to Type 1 diabetes. Furthermore, studies of T cell reactivity might reveal immunogenic determinants not seen with sera, or more sensitive serological measurements, perhaps for additional determinants might be required.
